Omeros Corporation (NASDAQ:OMER)’s share price rose 5.2% during trading on Tuesday . The company traded as high as $12.48 and last traded at $12.35, with a volume of 567,284 shares traded. The stock had previously closed at $11.74.

Several equities analysts have commented on OMER shares. Maxim Group reiterated a “buy” rating and set a $30.00 price target on shares of Omeros Corporation in a report on Thursday, May 19th. Cantor Fitzgerald started coverage on Omeros Corporation in a report on Thursday, June 2nd. They set a “buy” rating and a $21.00 price target on the stock. FBR & Co reiterated an “outperform” rating and set a $38.00 price target on shares of Omeros Corporation in a report on Wednesday, June 29th. WBB Securities reiterated a “buy” rating and set a $75.00 price target on shares of Omeros Corporation in a report on Tuesday, June 14th. Finally, Wedbush reiterated an “outperform” rating and set a $62.00 price target on shares of Omeros Corporation in a report on Tuesday, May 10th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $38.22.

The stock’s market capitalization is $473.53 million. The company has a 50-day moving average of $11.12 and a 200 day moving average of $12.29.

Omeros Corporation (NASDAQ:OMER) last announced its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.11. The company earned $7.40 million during the quarter, compared to analyst estimates of $8.79 million. During the same period in the prior year, the company posted ($0.51) EPS. The firm’s revenue was up 1797.4% compared to the same quarter last year. Equities analysts predict that Omeros Corporation will post ($1.76) EPS for the current year.

In related news, VP Marcia S. Kelbon sold 15,900 shares of the company’s stock in a transaction on Monday, May 16th. The stock was sold at an average price of $9.94, for a total transaction of $158,046.00. Following the completion of the sale, the vice president now directly owns 179,497 shares in the company, valued at approximately $1,784,200.18. The sale was disclosed in a filing with the SEC, which is available through this link.

Other institutional investors have recently bought and sold shares of the company. Nationwide Fund Advisors increased its position in Omeros Corporation by 183.9% in the fourth quarter. Nationwide Fund Advisors now owns 69,700 shares of the biopharmaceutical company’s stock valued at $1,096,000 after buying an additional 45,145 shares in the last quarter. California State Teachers Retirement System increased its position in Omeros Corporation by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 70,144 shares of the biopharmaceutical company’s stock valued at $1,103,000 after buying an additional 1,249 shares in the last quarter. Mutual of America Capital Management LLC increased its position in Omeros Corporation by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 116,171 shares of the biopharmaceutical company’s stock valued at $1,827,000 after buying an additional 694 shares in the last quarter. Brown Advisory Inc. increased its position in Omeros Corporation by 44.6% in the fourth quarter. Brown Advisory Inc. now owns 529,699 shares of the biopharmaceutical company’s stock valued at $8,332,000 after buying an additional 163,306 shares in the last quarter. Finally, Bank of Montreal Can increased its position in Omeros Corporation by 52.0% in the fourth quarter. Bank of Montreal Can now owns 1,327,706 shares of the biopharmaceutical company’s stock valued at $20,885,000 after buying an additional 454,055 shares in the last quarter.

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product Omidria is approved in the United States for use during cataract surgery or intraocular lens (IOL), which is replacement surgery, to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.